News/ News/ R&D Intercept hit hard as NASH trial misses the mark Phil Taylor hepatology, Intercept Pharmaceuticals, NASH, obeticholic acid 0 Comment Intercept Pharma’s hopes of getting its non-alcoholic steatohepatitis (NASH) therapy obeticholic acid (OCA) in the US may have Share X Intercept hit hard as NASH trial misses the mark https://pharmaphorum.com/news/intercept-hit-hard-as-nash-trial-misses-the-mark/
News/ News/ R&D Intercept CEO lays into FDA after NASH drug rejection Richard Staines fda, Intercept Pharmaceuticals, NASH, obeticholic acid, regulation 0 Comment Intercept Pharmaceuticals has accused the FDA of moving the goalposts during its review of a potential blockbuster drug for the fatty Share X Intercept CEO lays into FDA after NASH drug rejection https://pharmaphorum.com/news/intercept-ceo-lays-into-fda-after-nash-drug-rejection/
hepatology, Intercept Pharmaceuticals, NASH, obeticholic acid
0 Comment
